甲基转移酶
生物
DNMT1型
核糖核酸
2019年冠状病毒病(COVID-19)
酶
病毒复制
翻译(生物学)
冠状病毒
小分子
病毒学
计算生物学
生物化学
DNA
病毒
疾病
甲基化
基因
信使核糖核酸
传染病(医学专业)
病理
医学
作者
Souradeep Basu,Tiffany Mak,Rachel Ulferts,Mary Wu,Tom D Deegan,Ryo Fujisawa,Kang Hai Tan,Chew Leng Lim,Clovis Basier,Berta Canal,Joseph Curran,Lucy S. Drury,Allison W McClure,Emma Roberts,Florian Weissmann,Theresa U. Zeisner,Rupert Beale,Victoria H. Cowling,Michael D. Howell,Karim Labib,John F.X. Diffley
摘要
The COVID-19 pandemic has presented itself as one of the most critical public health challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae family to cause a fatal disease in humans. There is currently only one antiviral compound, remdesivir, that can be used for the treatment of COVID-19. To identify additional potential therapeutics, we investigated the enzymatic proteins encoded in the SARS-CoV-2 genome. In this study, we focussed on the viral RNA cap methyltransferases, which play key roles in enabling viral protein translation and facilitating viral escape from the immune system. We expressed and purified both the guanine-N7 methyltransferase nsp14, and the nsp16 2'-O-methyltransferase with its activating cofactor, nsp10. We performed an in vitro high-throughput screen for inhibitors of nsp14 using a custom compound library of over 5000 pharmaceutical compounds that have previously been characterised in either clinical or basic research. We identified four compounds as potential inhibitors of nsp14, all of which also showed antiviral capacity in a cell-based model of SARS-CoV-2 infection. Three of the four compounds also exhibited synergistic effects on viral replication with remdesivir.
科研通智能强力驱动
Strongly Powered by AbleSci AI